The gene expression signature associated with TP 53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under‐expression of TP 53 and other genes on chromosome 17p
In chronic lymphocytic leukaemia ( CLL ), TP 53 mutation and deletion are strongly associated with one another and with adverse clinical outcome. Mutant TP 53 protein typically accumulates to high levels and has been reported to have transcriptional regulatory activity distinct from that of wild‐typ...
Gespeichert in:
Veröffentlicht in: | British journal of haematology 2013-01, Vol.160 (1), p.53-62 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In chronic lymphocytic leukaemia (
CLL
),
TP
53
mutation and deletion are strongly associated with one another and with adverse clinical outcome. Mutant
TP
53 protein typically accumulates to high levels and has been reported to have transcriptional regulatory activity distinct from that of wild‐type
TP
53. To investigate whether such an effect is relevant to
CLL
, carefully balanced primary
CLL
samples with or without
TP
53
mutation/deletion were compared for their gene expression profiles using high‐density
DNA
microarrays. Ninety‐six and eight differentially expressed genes were identified, respectively, using two alternative statistical approaches with different stringencies. None of the differentially expressed genes were known to be regulated by mutant
TP
53, and only four of the 67 under‐expressed genes were known transcriptional targets of wild‐type
TP
53. Significantly, both approaches showed that gene under‐expression was the dominant feature of
TP
53
‐mutant
CLL
samples. Furthermore, a disproportionate number of the under‐expressed genes were located on chromosome 17p, the most significant being
TP
53
itself. Together, these results indicate that any transcriptional regulatory effects of mutant
TP
53 in
CLL
cells are overshadowed by the under‐expression of co‐deleted
TP
53
and other genes on chromosome 17p. Our findings have implications for emerging therapeutic strategies that target mutant
TP
53. |
---|---|
ISSN: | 0007-1048 1365-2141 |
DOI: | 10.1111/bjh.12092 |